{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T15:53:17Z","timestamp":1765295597210,"version":"3.46.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T00:00:00Z","timestamp":1757721600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T00:00:00Z","timestamp":1757721600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"the Key Research and Development Program of Hubei Province of China","award":["No. 2021BCA116"],"award-info":[{"award-number":["No. 2021BCA116"]}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82003205","82072736","82373123","82473175"],"award-info":[{"award-number":["82003205","82072736","82373123","82473175"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Natural Science Foundation of Hubei Province of China","award":["No. 2024AFB655"],"award-info":[{"award-number":["No. 2024AFB655"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1245\/s10434-025-18347-w","type":"journal-article","created":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T17:37:51Z","timestamp":1757785071000},"page":"235-245","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Oxidative Stress Inflammation Score is the Optimal Inflammatory Prognostic Indicator for Patients with Locally Advanced Gastric Cancer Receiving Neoadjuvant Immunochemotherapy: A Multicenter Retrospective Cohort Study"],"prefix":"10.1245","volume":"33","author":[{"given":"Tianhao","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianing","family":"Ding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuanfei","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shijun","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiong","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Duofei","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaohang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaixiong","family":"Tao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuping","family":"Yin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,9,13]]},"reference":[{"issue":"3","key":"18347_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349. https:\/\/doi.org\/10.3322\/caac.21660.","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"18347_CR2","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/S1470-2045(23)00541-7","volume":"25","author":"K Shitara","year":"2024","unstructured":"Shitara K, Rha SY, Wyrwicz LS, et al. Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study. Lancet Oncol. 2024;25(2):212\u201324. https:\/\/doi.org\/10.1016\/S1470-2045(23)00541-7.","journal-title":"Lancet Oncol."},{"issue":"2","key":"18347_CR3","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/S1470-2045(21)00692-6","volume":"23","author":"YK Kang","year":"2022","unstructured":"Kang YK, Chen LT, Ryu MH, et al. Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2022;23(2):234\u201347. https:\/\/doi.org\/10.1016\/S1470-2045(21)00692-6.","journal-title":"Lancet Oncol"},{"issue":"10294","key":"18347_CR4","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","volume":"398","author":"YY Janjigian","year":"2021","unstructured":"Janjigian YY, Shitara K, Moehler M, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021;398(10294):27\u201340. https:\/\/doi.org\/10.1016\/S0140-6736(21)00797-2.","journal-title":"Lancet."},{"issue":"12","key":"18347_CR5","doi-asserted-by":"publisher","first-page":"8157","DOI":"10.1245\/s10434-024-16041-x","volume":"31","author":"X Sun","year":"2024","unstructured":"Sun X, Lyu J, Yang M, et al. Two-year outcomes and biomarker analysis of locally advanced gastric and gastroesophageal junction adenocarcinoma after neoadjuvant chemotherapy and immunotherapy from the phase II WuhanUHGI001 Trial. Ann Surg Oncol. 2024;31(12):8157\u201369. https:\/\/doi.org\/10.1245\/s10434-024-16041-x.","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"18347_CR6","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1186\/s13046-023-02730-0","volume":"42","author":"X Li","year":"2023","unstructured":"Li X, Wang Y, Zhai Z, et al. Predicting response to immunotherapy in gastric cancer via assessing perineural invasion-mediated inflammation in tumor microenvironment. J Exp Clin Cancer Res CR. 2023;42(1):206. https:\/\/doi.org\/10.1186\/s13046-023-02730-0.","journal-title":"J Exp Clin Cancer Res CR."},{"issue":"12","key":"18347_CR7","doi-asserted-by":"publisher","first-page":"4151","DOI":"10.1097\/JS9.0000000000000741","volume":"109","author":"Y Wu","year":"2023","unstructured":"Wu Y, Zhao J, Wang Z, et al. Association of systemic inflammatory markers and tertiary lymphoid structure with pathological complete response in gastric cancer patients receiving preoperative treatment: a retrospective cohort study. Int J Surg Lond Engl. 2023;109(12):4151\u201361. https:\/\/doi.org\/10.1097\/JS9.0000000000000741.","journal-title":"Int J Surg Lond Engl"},{"issue":"1","key":"18347_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12957-021-02457-2","volume":"20","author":"X Zhaojun","year":"2022","unstructured":"Zhaojun X, Xiaobin C, Juan A, et al. Correlation analysis between preoperative systemic immune inflammation index and prognosis of patients after radical gastric cancer surgery: based on propensity score matching method. World J Surg Oncol. 2022;20(1):1. https:\/\/doi.org\/10.1186\/s12957-021-02457-2.","journal-title":"World J Surg Oncol"},{"issue":"2","key":"18347_CR9","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s10120-018-0854-6","volume":"22","author":"JX Lin","year":"2019","unstructured":"Lin JX, Lin JP, Xie JW, et al. Prognostic importance of the preoperative modified systemic inflammation score for patients with gastric cancer. Gastric Cancer. 2019;22(2):403\u201312. https:\/\/doi.org\/10.1007\/s10120-018-0854-6.","journal-title":"Gastric Cancer"},{"issue":"4","key":"18347_CR10","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1016\/j.clnu.2019.05.009","volume":"39","author":"Y Okugawa","year":"2020","unstructured":"Okugawa Y, Toiyama Y, Yamamoto A, et al. Lymphocyte-to-C-reactive protein ratio and score are clinically feasible nutrition-inflammation markers of outcome in patients with gastric cancer. Clin Nutr Edinb Scotl. 2020;39(4):1209\u201317. https:\/\/doi.org\/10.1016\/j.clnu.2019.05.009.","journal-title":"Clin Nutr Edinb Scotl."},{"issue":"4","key":"18347_CR11","doi-asserted-by":"publisher","first-page":"828","DOI":"10.3390\/cancers16040828","volume":"16","author":"Z Pelc","year":"2024","unstructured":"Pelc Z, S\u0119d\u0142ak K, Mlak R, et al. Prognostic value of inflammatory burden index in advanced gastric cancer patients undergoing multimodal treatment. Cancers. 2024;16(4):828. https:\/\/doi.org\/10.3390\/cancers16040828.","journal-title":"Cancers"},{"issue":"11","key":"18347_CR12","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1136\/gutjnl-2016-313075","volume":"66","author":"TT Wang","year":"2017","unstructured":"Wang TT, Zhao YL, Peng LS, et al. Tumour-activated neutrophils in gastric cancer foster immune suppression and disease progression through GM-CSF-PD-L1 pathway. Gut. 2017;66(11):1900\u201311. https:\/\/doi.org\/10.1136\/gutjnl-2016-313075.","journal-title":"Gut"},{"issue":"1","key":"18347_CR13","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s13046-018-1003-0","volume":"38","author":"S Li","year":"2019","unstructured":"Li S, Cong X, Gao H, et al. Tumor-associated neutrophils induce EMT by IL-17a to promote migration and invasion in gastric cancer cells. J Exp Clin Cancer Res CR. 2019;38(1):6. https:\/\/doi.org\/10.1186\/s13046-018-1003-0.","journal-title":"J Exp Clin Cancer Res CR."},{"issue":"1","key":"18347_CR14","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1186\/s12916-022-02506-x","volume":"20","author":"M Zhu","year":"2022","unstructured":"Zhu M, Ma Z, Zhang X, et al. C-reactive protein and cancer risk: a pan-cancer study of prospective cohort and Mendelian randomization analysis. BMC Med. 2022;20(1):301. https:\/\/doi.org\/10.1186\/s12916-022-02506-x.","journal-title":"BMC Med"},{"issue":"11","key":"18347_CR15","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1016\/j.freeradbiomed.2010.09.006","volume":"49","author":"S Reuter","year":"2010","unstructured":"Reuter S, Gupta SC, Chaturvedi MM, Aggarwal BB. Oxidative stress, inflammation, and cancer: how are they linked? Free Radic Biol Med. 2010;49(11):1603\u201316. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2010.09.006.","journal-title":"Free Radic Biol Med"},{"key":"18347_CR16","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1146\/annurev-cancerbio-041916-065808","volume":"1","author":"CR Reczek","year":"2017","unstructured":"Reczek CR, Chandel NS. The two faces of reactive oxygen species in cancer. Annu Rev Cancer Biol. 2017;1:79\u201398. https:\/\/doi.org\/10.1146\/annurev-cancerbio-041916-065808.","journal-title":"Annu Rev Cancer Biol"},{"issue":"5","key":"18347_CR17","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646\u201374. https:\/\/doi.org\/10.1016\/j.cell.2011.02.013.","journal-title":"Cell"},{"key":"18347_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2021.101891","volume":"42","author":"KB Kennel","year":"2021","unstructured":"Kennel KB, Greten FR. Immune cell - produced ROS and their impact on tumor growth and metastasis. Redox Biol. 2021;42:101891. https:\/\/doi.org\/10.1016\/j.redox.2021.101891.","journal-title":"Redox Biol."},{"issue":"1","key":"18347_CR19","doi-asserted-by":"publisher","first-page":"102","DOI":"10.3390\/antiox11010102","volume":"11","author":"JG McLarnon","year":"2021","unstructured":"McLarnon JG. A leaky blood-brain barrier to fibrinogen contributes to oxidative damage in Alzheimer\u2019s disease. Antioxid Basel Switz. 2021;11(1):102. https:\/\/doi.org\/10.3390\/antiox11010102.","journal-title":"Antioxid Basel Switz."},{"issue":"2","key":"18347_CR20","doi-asserted-by":"publisher","first-page":"191","DOI":"10.17305\/bjbms.2018.2306","volume":"18","author":"M Sandesc","year":"2018","unstructured":"Sandesc M, Rogobete AF, Bedreag OH, et al. Analysis of oxidative stress-related markers in critically ill polytrauma patients: An observational prospective single-center study. Bosn J Basic Med Sci. 2018;18(2):191\u20137. https:\/\/doi.org\/10.17305\/bjbms.2018.2306.","journal-title":"Bosn J Basic Med Sci."},{"key":"18347_CR21","doi-asserted-by":"publisher","first-page":"672","DOI":"10.17179\/excli2015-245","volume":"14","author":"S Periasamy","year":"2015","unstructured":"Periasamy S, Hsu DZ, Fu YH, Liu MY. Sleep deprivation-induced multi-organ injury: role of oxidative stress and inflammation. EXCLI J. 2015;14:672\u201383. https:\/\/doi.org\/10.17179\/excli2015-245.","journal-title":"EXCLI J."},{"issue":"12","key":"18347_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2024.108658","volume":"50","author":"H Zheng","year":"2024","unstructured":"Zheng H, Zheng H, Wei L, et al. Risk stratification models incorporating oxidative stress factors to predict survival and recurrence in patients with gastric cancer after radical gastrectomy: A real-world multicenter study. Eur J Surg Oncol. 2024;50(12):108658. https:\/\/doi.org\/10.1016\/j.ejso.2024.108658.","journal-title":"Eur J Surg Oncol."},{"issue":"1","key":"18347_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10120-016-0622-4","volume":"20","author":"Japanese Gastric Cancer Association","year":"2017","unstructured":"Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2014 (ver 4). Gastric Cancer Off J Int Gastric Cancer Assoc Jpn Gastric Cancer Assoc. 2017;20(1):1\u201319. https:\/\/doi.org\/10.1007\/s10120-016-0622-4.","journal-title":"Gastric Cancer Off J Int Gastric Cancer Assoc Jpn Gastric Cancer Assoc"},{"issue":"2","key":"18347_CR24","doi-asserted-by":"publisher","first-page":"93","DOI":"10.3322\/caac.21388","volume":"67","author":"MB Amin","year":"2017","unstructured":"Amin MB, Greene FL, Edge SB, et al. The eighth edition AJCC cancer staging manual: continuing to build a bridge from a population-based to a more \u201cpersonalized\u201d approach to cancer staging. CA Cancer J Clin. 2017;67(2):93\u20139. https:\/\/doi.org\/10.3322\/caac.21388.","journal-title":"CA Cancer J Clin"},{"issue":"21","key":"18347_CR25","doi-asserted-by":"publisher","first-page":"7252","DOI":"10.1158\/1078-0432.CCR-04-0713","volume":"10","author":"RL Camp","year":"2004","unstructured":"Camp RL, Dolled-Filhart M, Rimm DL. X-tile: A new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res. 2004;10(21):7252\u20139. https:\/\/doi.org\/10.1158\/1078-0432.CCR-04-0713.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"18347_CR26","doi-asserted-by":"publisher","first-page":"167","DOI":"10.6004\/jnccn.2022.0008","volume":"20","author":"JA Ajani","year":"2022","unstructured":"Ajani JA, D\u2019Amico TA, Bentrem DJ, et al. Gastric cancer, version 2.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw JNCCN. 2022;20(2):167\u201392. https:\/\/doi.org\/10.6004\/jnccn.2022.0008.","journal-title":"J Natl Compr Cancer Netw JNCCN"},{"issue":"2","key":"18347_CR27","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.clnu.2023.01.005","volume":"42","author":"P Ding","year":"2023","unstructured":"Ding P, Wu H, Liu P, et al. The inflammatory burden index: A promising prognostic predictor in patients with locally advanced gastric cancer. Clin Nutr Edinb Scotl. 2023;42(2):247\u20138. https:\/\/doi.org\/10.1016\/j.clnu.2023.01.005.","journal-title":"Clin Nutr Edinb Scotl"},{"issue":"4","key":"18347_CR28","doi-asserted-by":"publisher","first-page":"791","DOI":"10.3390\/jcm10040791","volume":"10","author":"S Yasui","year":"2021","unstructured":"Yasui S, Takata T, Kamitani Y, et al. Neutrophil-to-lymphocyte ratio is a useful marker for predicting histological types of early gastric cancer. J Clin Med. 2021;10(4):791. https:\/\/doi.org\/10.3390\/jcm10040791.","journal-title":"J Clin Med."},{"issue":"2","key":"18347_CR29","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1245\/s10434-020-09074-5","volume":"28","author":"ST McSorley","year":"2021","unstructured":"McSorley ST, Lau HYN, McIntosh D, Forshaw MJ, McMillan DC, Crumley AB. Staging the tumor and staging the host: pretreatment combined neutrophil lymphocyte ratio and modified glasgow prognostic score is associated with overall survival in patients with esophagogastric cancers undergoing treatment with curative intent. Ann Surg Oncol. 2021;28(2):722\u201331. https:\/\/doi.org\/10.1245\/s10434-020-09074-5.","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"18347_CR30","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-007054","volume":"11","author":"M He","year":"2023","unstructured":"He M, Chen ZF, Zhang L, et al. Associations of subcutaneous fat area and Systemic Immune-inflammation Index with survival in patients with advanced gastric cancer receiving dual PD-1 and HER2 blockade. J Immunother Cancer. 2023;11(6):e007054. https:\/\/doi.org\/10.1136\/jitc-2023-007054.","journal-title":"J Immunother Cancer"},{"issue":"10","key":"18347_CR31","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1038\/nrclinonc.2015.105","volume":"12","author":"SM Crusz","year":"2015","unstructured":"Crusz SM, Balkwill FR. Inflammation and cancer: advances and new agents. Nat Rev Clin Oncol. 2015;12(10):584\u201396. https:\/\/doi.org\/10.1038\/nrclinonc.2015.105.","journal-title":"Nat Rev Clin Oncol"},{"issue":"11","key":"18347_CR32","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1038\/nrc3611","volume":"13","author":"E Elinav","year":"2013","unstructured":"Elinav E, Nowarski R, Thaiss CA, Hu B, Jin C, Flavell RA. Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms. Nat Rev Cancer. 2013;13(11):759\u201371. https:\/\/doi.org\/10.1038\/nrc3611.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"18347_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41392-021-00658-5","volume":"6","author":"H Zhao","year":"2021","unstructured":"Zhao H, Wu L, Yan G, et al. Inflammation and tumor progression: signaling pathways and targeted intervention. Signal Transduct Target Ther. 2021;6(1):1\u201346. https:\/\/doi.org\/10.1038\/s41392-021-00658-5.","journal-title":"Signal Transduct Target Ther"},{"issue":"5","key":"18347_CR34","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1038\/nri.2017.142","volume":"18","author":"K Taniguchi","year":"2018","unstructured":"Taniguchi K, Karin M. NF-\u03baB, inflammation, immunity and cancer: coming of age. Nat Rev Immunol. 2018;18(5):309\u201324. https:\/\/doi.org\/10.1038\/nri.2017.142.","journal-title":"Nat Rev Immunol"},{"issue":"20","key":"18347_CR35","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1182\/blood-2018-11-844548","volume":"133","author":"MA Giese","year":"2019","unstructured":"Giese MA, Hind LE, Huttenlocher A. Neutrophil plasticity in the tumor microenvironment. Blood. 2019;133(20):2159\u201367. https:\/\/doi.org\/10.1182\/blood-2018-11-844548.","journal-title":"Blood."},{"issue":"7","key":"18347_CR36","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.it.2019.04.013","volume":"40","author":"A Hidalgo","year":"2019","unstructured":"Hidalgo A, Chilvers ER, Summers C, Koenderman L. The neutrophil life cycle. Trends Immunol. 2019;40(7):584\u201397. https:\/\/doi.org\/10.1016\/j.it.2019.04.013.","journal-title":"Trends Immunol."},{"key":"18347_CR37","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.589022","volume":"11","author":"Y Chen","year":"2021","unstructured":"Chen Y, Zhang C, Peng Z, et al. Association of lymphocyte-to-monocyte ratio with survival in advanced gastric cancer patients treated with immune checkpoint inhibitor. Front Oncol. 2021;11:589022. https:\/\/doi.org\/10.3389\/fonc.2021.589022.","journal-title":"Front Oncol"},{"key":"18347_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2024.103208","volume":"73","author":"D Li","year":"2024","unstructured":"Li D, Yu Q, Wu R, et al. Interactions between oxidative stress and senescence in cancer: Mechanisms, therapeutic implications, and future perspectives. Redox Biol. 2024;73:103208. https:\/\/doi.org\/10.1016\/j.redox.2024.103208.","journal-title":"Redox Biol"},{"issue":"7","key":"18347_CR39","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1038\/nrd2803","volume":"8","author":"D Trachootham","year":"2009","unstructured":"Trachootham D, Alexandre J, Huang P. Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? Nat Rev Drug Discov. 2009;8(7):579\u201391. https:\/\/doi.org\/10.1038\/nrd2803.","journal-title":"Nat Rev Drug Discov"},{"issue":"2","key":"18347_CR40","doi-asserted-by":"publisher","first-page":"F119","DOI":"10.1136\/fn.88.2.f119","volume":"88","author":"C Dani","year":"2003","unstructured":"Dani C, Martelli E, Bertini G, et al. Plasma bilirubin level and oxidative stress in preterm infants. Arch Dis Child Fetal Neonatal Ed. 2003;88(2):F119\u201323. https:\/\/doi.org\/10.1136\/fn.88.2.f119.","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"issue":"5","key":"18347_CR41","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/0891-5849(94)90169-4","volume":"17","author":"E Shacter","year":"1994","unstructured":"Shacter E, Williams JA, Lim M, Levine RL. Differential susceptibility of plasma proteins to oxidative modification: examination by western blot immunoassay. Free Radic Biol Med. 1994;17(5):429\u201337. https:\/\/doi.org\/10.1016\/0891-5849(94)90169-4.","journal-title":"Free Radic Biol Med"},{"key":"18347_CR42","doi-asserted-by":"publisher","first-page":"104625","DOI":"10.1016\/j.critrevonc.2025.104625","volume":"207","author":"Y Zhang","year":"2025","unstructured":"Zhang Y, Li Z, Zhang J, et al. Fibrinogen: A new player and target on the formation of pre-metastatic niche in tumor metastasis. Crit Rev Oncol Hematol. 2025;207:104625. https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104625.","journal-title":"Crit Rev Oncol Hematol."},{"issue":"45","key":"18347_CR43","doi-asserted-by":"publisher","first-page":"3289","DOI":"10.1038\/s41388-023-02836-x","volume":"42","author":"X Liu","year":"2023","unstructured":"Liu X, Lv M, Zhang W, Zhan Q. Dysregulation of cholesterol metabolism in cancer progression. Oncogene. 2023;42(45):3289\u2013302. https:\/\/doi.org\/10.1038\/s41388-023-02836-x.","journal-title":"Oncogene."},{"issue":"5","key":"18347_CR44","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1007\/s13402-022-00694-5","volume":"45","author":"J Gu","year":"2022","unstructured":"Gu J, Zhu N, Li HF, et al. Cholesterol homeostasis and cancer: a new perspective on the low-density lipoprotein receptor. Cell Oncol Dordr Neth. 2022;45(5):709\u201328. https:\/\/doi.org\/10.1007\/s13402-022-00694-5.","journal-title":"Cell Oncol Dordr Neth."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-18347-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-025-18347-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-18347-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T14:09:29Z","timestamp":1765289369000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-025-18347-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,13]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["18347"],"URL":"https:\/\/doi.org\/10.1245\/s10434-025-18347-w","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"type":"print","value":"1068-9265"},{"type":"electronic","value":"1534-4681"}],"subject":[],"published":{"date-parts":[[2025,9,13]]},"assertion":[{"value":"22 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}},{"value":"The study has been approved by the ethics committees of all the medical centers. Due to the retrospective nature of this study, informed consent from patients was not required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}